• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Analyst initiated coverage on First Tracks Biotherapeutics with a new price target

    4/23/26 7:56:07 AM ET
    $TRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRAX alert in real time by email
    Analyst initiated coverage of First Tracks Biotherapeutics with a rating of Overweight and set a new price target of $31.00
    Get the next $TRAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TRAX

    DatePrice TargetRatingAnalyst
    4/23/2026$31.00Overweight
    Analyst
    4/22/2026$40.00Overweight
    Barclays
    4/21/2026$45.00Buy
    UBS
    More analyst ratings

    $TRAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Tamboli Ajim

    3 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)

    4/23/26 6:08:19 PM ET
    $TRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Tamboli Ajim

    4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)

    4/23/26 6:08:54 PM ET
    $TRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Ecor1 Capital, Llc

    4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)

    4/22/26 5:07:53 PM ET
    $TRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRAX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by First Tracks Biotherapeutics Inc.

    SCHEDULE 13G - First Tracks Biotherapeutics, Inc. (0002091349) (Subject)

    4/22/26 5:09:57 PM ET
    $TRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on First Tracks Biotherapeutics with a new price target

    Analyst initiated coverage of First Tracks Biotherapeutics with a rating of Overweight and set a new price target of $31.00

    4/23/26 7:56:07 AM ET
    $TRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on First Tracks Biotherapeutics with a new price target

    Barclays initiated coverage of First Tracks Biotherapeutics with a rating of Overweight and set a new price target of $40.00

    4/22/26 7:56:43 AM ET
    $TRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS initiated coverage on First Tracks Biotherapeutics with a new price target

    UBS initiated coverage of First Tracks Biotherapeutics with a rating of Buy and set a new price target of $45.00

    4/21/26 7:33:40 AM ET
    $TRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care